MEK1 and MEK2 differentially regulate human insulin- And insulin glargine-induced human bladder cancer T24 cell proliferation

Chinese Medical Journal

Volumn 125, Issue 23, 2012, Pages 4197-4201

  Liu, Shan Ying ^a   Liang, Ying ^a   Lin, Tian Xin ^a   Su, Fang ^a   Liang, Wei Wen ^a   Heemann, Uwe ^b   Li, Yan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bladder cancer; Glargine; Insulin; MEK; Proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; HUMAN INSULIN; INSULIN GLARGINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLAVONOIDS; HUMANS; INSULIN; INSULIN, LONG-ACTING; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS;

EID: 84870747418     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.23.007     Document Type: Article

References (26)

1. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-2823.
2. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54: 2009-2015.
3. Mackenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: Evidence from a case-control study in New England. Cancer 2011; 117: 1552-1556.
4. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744.
5. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754.
6. Staiger K, Hennige AM, Staiger H, Häring HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007; 39: 65-67.
7. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 2008; 81: 269-277.
8. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract 2011; 91: 177-182.
9. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008; 114: 38-44.
10. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
11. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
12. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 2010; 53: 2667-2675
13. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010; 53: 1743-1753.
14. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
15. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999; 18: 664-674.
16. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993; 73: 381-393.
17. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995; 269: 403-407.
18. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -indepen- dent mechanisms. Science 1999; 286: 1358-1362.
19. Liu SY, Liang QJ, Lin TX, Fan XL, Liang Y, Heemann U, et al. Lipopolysaccharide-enhanced early proliferation of insulin secreting NIT-1 cell is associated with nuclear factor-kappaB-mediated inhibition of caspase 3 cleavage. Chin Med J 2011; 124: 3652-3656.
20. Ussar S, Voss T. MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem 2004; 279: 43861-43869.
21. Zhou L, Tan X, Kamohara H, Wang W, Wang B, Liu J, et al. MEK1 and MEK2 isoforms regulate distinct functions in pancreatic cancer cells. Oncol Rep 2010; 24: 251-255.
22. Gailhouste L, Ezan F, Bessard A, Frémin C, Rageul J, Langouët S, et al. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo. Int J Cancer 2010; 126: 1367-1377.
23. Kim DI, Lee SJ, Lee SB, Park K, Kim WJ, Moon SK. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis 2008; 29: 1701-1709.
24. Kim WJ, Lee SJ, Choi YD, Moon SK. Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation. Int J Mol Med 2010; 25: 635-641.
25. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1995; 92: 7686-7689.
26. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270: 27489-27494.